CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model

Sheng Cui1, Yoo Jin Shin1, Xianying Fang1

  • 1Transplantation Research Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Insights

CRISPR/Cas9 gene editing successfully suppressed A4GALT, rescuing Fabry disease nephropathy (FDN) phenotypes in kidney organoids. This approach offers a potential therapeutic strategy for FDN.

Area of Science:

  • Biotechnology
  • Genetics
  • Stem Cell Biology

Background:

  • Fabry disease nephropathy (FDN) is a genetic disorder characterized by alpha-galactosidase-A deficiency, leading to globotriaosylceramide accumulation.
  • Current treatments for FDN are limited, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

  • To investigate the potential of CRISPR/Cas9-mediated suppression of A4GALT to rescue FDN phenotypes.
  • To utilize human induced pluripotent stem cells (hiPSCs)-derived kidney organoids as a model system for FDN research.

Main Methods:

  • Generated FDN patient-derived hiPSCs and GLA-knockout (KO) hiPSCs.
  • Performed A4GALT KO in both FDN and GLA-KO hiPSCs using CRISPR/Cas9.
  • Developed kidney organoids from engineered hiPSCs and analyzed alpha-galactosidase-A (α-GalA) activity, globotriaosylceramide (Gb-3) deposition, and gene expression.

Main Results:

  • Engineered hiPSCs maintained pluripotency without chromosomal abnormalities.
  • A4GALT KO successfully reduced A4GALT expression in kidney organoids.
  • CRISPR/Cas9-mediated A4GALT suppression rescued FDN phenotypes, including Gb-3 deposition and normalized gene expression patterns in kidney organoids.

Conclusions:

  • CRISPR/Cas9-mediated A4GALT suppression effectively rescues FDN phenotypes in a hiPSC-derived kidney organoid model.
  • Targeting A4GALT presents a promising therapeutic avenue for treating Fabry disease nephropathy.